Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Apyx Medical (APYX) Short term Debt (2016 - 2023)

Apyx Medical filings provide 12 years of Short term Debt readings, the most recent being $8.9 million for Q2 2023.

On a quarterly basis, Short term Debt changed N/A to $8.9 million in Q2 2023 year-over-year; TTM through Jun 2023 was $8.9 million, a N/A change, with the full-year FY2019 number at $140000.0, changed N/A from a year prior.
Short term Debt hit $8.9 million in Q2 2023 for Apyx Medical, up from $8.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $8.9 million in Q2 2023 to a low of $140000.0 in Q4 2019.
Median Short term Debt over the past 3 years was $140000.0 (2019), compared with a mean of $3.0 million.